Pfizer Rethinks German Investment Over Drug Price Caps

Bourla’s correspondence highlights a growing unease among major industry players regarding the long-term viability of the German market. While Pfizer has yet to specify which projects face the chopping block, the message signals a clear shift in corporate sentiment. This reaction mirrors moves by Eli Lilly and Boehringer Ingelheim, both of which have recently signaled caution regarding their German operations.

At the heart of the dispute lies the government's push to limit health insurance expenditures, a policy that pharmaceutical firms argue stifles innovation and market entry. As companies navigate a shifting international landscape, including intense scrutiny over U.S. pricing, the German legislative environment has become a central point of contention. Executives are now demanding conditions that justify the high cost of launching new medicines, warning that punitive pricing structures threaten the future of local medical development.